SCHEMBL2010599

SCHEMBL2010599

CCOC(=O)COc1cc(O)c(C(=O)CN)c(O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.49
GAA P10253 3/20 0.46
NPSR1 Q6W5P4 2/20 0.46
NR1H2 P55055 1/20 0.45
NR1H3 Q13133 1/20 0.45
HSD17B10 Q99714 2/20 0.44
KDM4E B2RXH2 1/20 0.44
CYP3A4 P08684 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
MAPT P10636 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
PTGS1 P23219 1/20 0.41
DRD3 P35462 1/20 0.41
SLC5A1 P13866 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2010988 0.90 CYP3A4 (0.44) HPGDGAANPSR1CYP3A4SMN1; SMN2
SCHEMBL2004229 0.82 HPGD (0.65) HPGDGAANPSR1HSD17B10KDM4E
SCHEMBL2010800 0.79 HPGD (0.55) HPGDGAANPSR1HSD17B10KDM4E
SCHEMBL2010751 0.76 GAA (0.59) HPGDGAANPSR1HSD17B10KDM4E
SCHEMBL2010341 0.75 HMGCR (0.53) HPGDGAANPSR1HSD17B10SMN1; SMN2
SCHEMBL15601402 0.75 GAA (0.50) HPGDGAANPSR1HSD17B10KDM4E
Hydrochloric Acid SCHEMBL11660184 0.75 GAA (0.57) HPGDGAANPSR1HSD17B10KDM4E
SCHEMBL2013912 0.74 HPGD (0.53) HPGDGAANPSR1HSD17B10KDM4E
SCHEMBL5361832 0.74 GAA (0.56) HPGDGAANPSR1HSD17B10KDM4E
SCHEMBL22542335 0.74 HPGD (0.63) HPGDGAANPSR1HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US disclosed
EP-1677783-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE Nicholas Piramal India Limited (IN) 2006-07-12 EP disclosed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE FGB, F13B, F2 HPGD 1551/4885GAA 3340/4885NPSR1 340/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 HPGD 1551/4885GAA 3340/4885NPSR1 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.